source
- Roche licenses Rona's ALK7 obesity candidate in $1.2 billion dealRoche has agreed to license an RNAi drug candidate targeting ALK7 from Chinese biotech Rona Therapeutics, with an upfront payment of $100 million and potential milestones up to $1.06 billion. The…
- BioNTech's head and neck cancer mRNA vaccine fails to extend progression-free survival in Phase 3 trialBioNTech reported that its experimental mRNA immunotherapy BNT113 did not meet its primary endpoint in a Phase 3 trial for a specific head and neck cancer, failing to improve progression-free survi…